A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT04712669
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 108 participants
- Sponsor
- Altavant Sciences GmbH
- Registry
-
NCT04712669
-
- Other papers using this trial's data
- Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial
- Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Canada, Czechia, France, Germany, Italy, Latvia, Moldova, Poland, Serbia, Spain, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04712669. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-15 (actual); primary completion 2023-06-05 (actual). Results posted on 2025-06-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- rodatristat ethyl 300 mg tablet BID
- Intervention (Drug)
- rodatristat ethyl 600 mg BID
- Intervention (Drug)
- Placebo
- Lead sponsor
- Altavant Sciences GmbH
Record details
- Record id
cardio:ct-nct04712669- Content hash
e0048fabfed4d6ad94673c75345ddba103bf9dd2cdbba0ab5cac77dd07e8615b